Comment to FDA re: draft guidance on allergen labeling

CSPI urges the agency to lay out a plan to proactively consider new allergens and develop controls for allergens prioritized under the proposed framework. We also urge FDA to develop an approach to prioritizing food intolerances not covered by the current guidance.